Q2 Earnings Miss Roundup: CEVA Inc, Medical Properties Trust, Heron Therapeutics, and inTest Corp

The Quick Take

• CEVA Inc (CEVA) missed Q2 revenue estimates with a GF Score of 60/100 signalling weak fundamental momentum across metrics.
• Medical Properties Trust (MPT) reported Q2 results reflecting continued pressure on its healthcare real estate portfolio.
• Heron Therapeutics (HRTX) is flagged as a potential value trap after Q2 miss with deteriorating GF Score metrics.
• inTest Corp (INTT) missed Q2 estimates as semiconductor test equipment demand cycles through a correction phase.

Synthesized from 4 sources — full coverage, sentiment breakdown, and forward signals below.

This Q2 earnings cluster captures four distinct US companies that all missed estimates and carry weak GuruFocus GF Scores, reflecting broad fundamental pressure across semiconductor IP, healthcare real estate, specialty pharma, and test equipment markets. CEVA Inc, which licenses semiconductor IP for wireless connectivity chips, faces a cyclical slowdown in device production volumes that is compressing its royalty revenue stream. With a GF Score of 60 out of 100 — placing it in the lower-quality zone of GuruFocus's framework — CEVA's fundamental momentum signals require careful scrutiny before any value case can be made.

Medical Properties Trust represents the most institutionally watched name in this cluster. The healthcare REIT has been navigating a complex period characterised by tenant credit issues, asset sales to reduce leverage, and market scepticism about the sustainability of its dividend. MPT's Q2 result continues a pattern of results that keep debt reduction and occupancy stabilisation at the centre of investor attention. Heron Therapeutics, a specialty pharma company, adds a clinical-stage complexity to the cluster — its value trap designation by GuruFocus reflects both the earnings miss and the challenge of commercialising pain management therapies in a competitive generics environment.

inTest Corp, a manufacturer of semiconductor test equipment, is a cycle-dependent business whose Q2 miss reflects the ongoing inventory correction in the semiconductor supply chain. Test equipment demand is a leading indicator of chip production ramp decisions, and the miss signals that fabless designers and foundries are still working through excess capacity from the 2021-2022 buildout. The GF Score cluster across these four names should be read as a sector-diversity earnings screen result rather than evidence of a common underlying thesis — each requires an independent fundamental assessment.